Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Emedastine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Emedastine SCHEMBL449580 | 1.00 | POLB (0.62) | POLB | |
| Emedastine SCHEMBL29846167 | 1.00 | POLB (0.62) | POLB | |
| Emedastine SCHEMBL41386 | 1.00 | POLB (0.62) | POLB | |
| Emedastine SCHEMBL1649085 | 1.00 | POLB (0.62) | POLB | |
| Emedastine SCHEMBL449581 | 1.00 | POLB (0.62) | POLB | |
| Emedastine SCHEMBL41385 | 1.00 | POLB (0.62) | POLB | |
| Fumaric Acid SCHEMBL10920208 | 0.93 | POLB (0.63) | POLB | |
| Fumaric Acid SCHEMBL10920204 | 0.93 | POLB (0.63) | POLB | |
| Emedastine SCHEMBL29770 | 0.91 | — | — | |
| Emedastine SCHEMBL29493445 | 0.91 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 946 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4590283-A1 | MUCOADHESIVE DRUG DELIVERY SYSTEMS AND METHODS OF USE | Madd Ophthalmics Ltd. (CA) | 2025-07-30 | — | — | EP | claimed |
| WO-2024059952-A1 | MUCOADHESIVE DRUG DELIVERY SYSTEMS AND METHODS OF USE | MADD OPHTHALMICS LTD. (CA) | 2024-03-28 | — | — | WO | claimed |
| US-20230285286-A1 | DRUG VEHICLE COMPOSITIONS AND METHODS OF USE THEREOF | PS THERAPY INC (US) | 2023-09-14 | — | — | US | claimed |
| US-20230102547-A1 | ANTERIOR SEGMENT DRUG DELIVERY | FORSIGHT VISION5, INC. | 2023-03-30 | — | — | US | claimed |
| EP-4108216-A1 | ANTERIOR SEGMENT DRUG DELIVERY | Forsight Vision5, Inc. (US) | 2022-12-28 | — | — | EP | claimed |
| EP-2437684-B1 | ANTERIOR SEGMENT DRUG DELIVERY | FORSIGHT VISION5 INC (US) | 2022-06-15 | — | — | EP | claimed |
| US-20210128351-A1 | ANTERIOR SEGMENT DRUG DELIVERY | FORSIGHT VISION5, INC. | 2021-05-06 | — | — | US | claimed |
| US-10736774-B2 | Anterior segment drug delivery | FORSIGHT VISION5, INC. (US) | 2020-08-11 | — | — | US | claimed |
| US-20190105198-A1 | ANTERIOR SEGMENT DRUG DELIVERY | FORSIGHT VISION5, INC. | 2019-04-11 | — | — | US | claimed |
| US-10004636-B2 | Anterior segment drug delivery | FORSIGHT VISION5, INC. (US) | 2018-06-26 | — | — | US | claimed |
| US-20080066741-A1 | METHODS AND SYSTEMS OF DELIVERING MEDICATION VIA INHALATION | HUNTER, CHARLES ERIC | 2008-03-20 | — | — | US | claimed |
| WO-2007092334-A1 | METHOD OF TREATING SLEEP DISORDERS | HYPNION, INC. (US) | 2007-08-16 | — | — | WO | claimed |
| EP-1250133-B1 | OPHTHALMIC ANTI-ALLERGY COMPOSITIONS SUITABLE FOR USE WITH CONTACT LENSES | ALCON INC (CH) | 2005-03-30 | — | — | EP | claimed |
| JP-2003520813-A | — | — | 2003-07-08 | — | — | JP | claimed |
| EP-1250133-A1 | OPHTHALMIC ANTI-ALLERGY COMPOSITIONS SUITABLE FOR USE WITH CONTACT LENSES | Alcon Universal, Ltd. (CH) | 2002-10-23 | — | — | EP | claimed |
| US-6375973-B2 | OLOPATADINE AND EMEDASTINE AND AN OPHTHALMICALLY ACCEPTABLE POLYMERIC QUATERNARY AMMONIUM COMPOUND AS A PRESERVATIVE | ALCON UNIVERSAL LTD. (CH) | 2002-04-23 | — | — | US | claimed |
| US-20010056093-A1 | Ophthalmic anti-allergy compositions suitable for use with contact lenses | ALCON UNIVERSAL, LTD. | 2001-12-27 | — | — | US | claimed |
| US-20010049369-A1 | Brimonidine compositions and methods for retinal degeneration | UNIVERSITY OF TENNESSEE RESEARCH CORPORATION, THE | 2001-12-06 | — | — | US | claimed |
| WO-2001054687-A1 | OPHTHALMIC ANTI-ALLERGY COMPOSITIONS SUITABLE FOR USE WITH CONTACT LENSES | ALCON UNIVERSAL LTD. (CH) | 2001-08-02 | — | — | WO | claimed |
| EP-0826371-A1 | EXTERNAL PREPARATION CONTAINING EMEDASTINE | KANEBO LTD. (JP) | 1998-03-04 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010049369-A1 | Brimonidine compositions and methods for retinal degeneration | NR2E3, MTNR1A, MTNR1B | POLB 3746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.